temozolomide has been researched along with oxadiazoles in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bouska, JJ; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Johnson, EF; Leverson, J; Liu, X; Luo, Y; Marcotte, PA; Olson, AM; Osterling, DJ; Penning, TD; Przytulinska, M; Rodriguez, LE; Shi, Y; Soni, N; Stavropoulos, J; Thomas, S; Tong, Y | 1 |
| Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Sugino, T; Yamaguchi, K | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K | 1 |
| Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Ito, M; Kiyohara, Y; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Yamaguchi, K | 1 |
| Bachmann, F; Dietrich, PY; Espinoza, FI; Genoud, V; Lane, HA; Marinari, E; McSheehy, P; Rochemont, V; Walker, PR | 1 |
6 other study(ies) available for temozolomide and oxadiazoles
| Article | Year |
|---|---|
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzimidazoles; Biological Availability; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous | 2009 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Methylation; Drug Synergism; Glutathione Transferase; Humans; Inhibitory Concentration 50; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Temozolomide | 2011 |
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms, Experimental; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Exome; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Male; Oxadiazoles; Protein Kinase Inhibitors; Quinolines; Signal Transduction; STAT3 Transcription Factor; Temozolomide; TOR Serine-Threonine Kinases | 2017 |
The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; HLA-A2 Antigen; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Knockout; Mice, Nude; Oxadiazoles; Quinolines; STAT3 Transcription Factor; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Brain Neoplasms; CD40 Antigens; Cell Line, Tumor; Cell Proliferation; CTLA-4 Antigen; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Glioblastoma; HMGB1 Protein; Immune Checkpoint Inhibitors; Interferon-gamma; Mice; Mitosis; Neoplasm Transplantation; Oxadiazoles; Programmed Cell Death 1 Receptor; Survival Rate; Temozolomide; Tumor Microenvironment | 2021 |